Advanced search
Publication Cover
Biomarkers in Medicine Volume 7, 2013 - Issue 4
Submit an article Journal homepage
175
Views
0
CrossRef citations to date
0
Altmetric
Research Article

CYFRA21-1 as a Serum Tumor Marker for Follow-Up Patients with Squamous Cell Lung Carcinoma and Oropharynx Squamous Cell Carcinoma

Lei Liu1 Department of Respiratory Medicine, the Fourth Affiliated Hospital of Harbin Medical University,No 37, Yi Yuan Street, Nan Gang District,Harbin150001,ChinaCorrespondence[email protected]
,
Bin Liu2 Department of Respiratory Medicine, the First Affiliated Hospital of Harbin Medical University,Harbin150001,China
,
Li-li Zhu1 Department of Respiratory Medicine, the Fourth Affiliated Hospital of Harbin Medical University,No 37, Yi Yuan Street, Nan Gang District,Harbin150001,China
&
Yu Li1 Department of Respiratory Medicine, the Fourth Affiliated Hospital of Harbin Medical University,No 37, Yi Yuan Street, Nan Gang District,Harbin150001,China
Pages 591-599 | Published online: 02 Aug 2013

References

  • Gudbjartsson T , SmáradottirA, SkúladóttirHet al. Lung cancer review. Laeknabladid 94, 297–311 (2008).
  • Hespanhol V , QueirogaH, MagalhaesA, SantosAR, CoelhoM, MarquesA. Survival predictors in advanced non-small cell lung cancer. Lung Cancer13, 253–267 (1995).
  • Welch HG , SchwartzLM, WoloshinS. Survival of cancer patients in Europe: are increasing 5-year survival rates evidence of success against cancer?JAMA283, 2975–2978 (2000).
  • Wieskopf B , DemangentC, PurohitAet al. CYFRA21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity and prognostic role. Chest 108, 163–169 (1995).
  • Liu L , LiuB, ZhuLL, ZhangW, LiY. Clinical significance of CYFRA21-1, Scc-Ag and telomerase activity in serum and pleural effusion of patients with squamous-cell lung cancer. Bioanalysis4(19), 2367–2374 (2012).
  • Takei Y , MinatoK, TsuchiyaSet al. CYFRA21-1: an indicator of survival and therapeutic effect in lung cancer. Oncol. 54, 43–47 (1997).
  • Pujol JL , MolinierO, EbertWet al. CYFRA21-1 is a prognostic determinant in non-small cell lung cancer: results of meta-analysis in 2063 patients. Br. J. Cancer 90, 2097–2105, 2004.
  • Niklinski J , BurzykowskiT, NiklinskaWet al. Preoperative CYFRA21-1 level as prognostic indicator in resected non small cell lung cancer. Eur. Respir. J. 12, 1424–1428 (1998).
  • Kulpa J , WójcikE, ReinfussM, KolodziejskiL. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin. Chem.48, 1931–2002 (1937).
  • Yi Y , LiB, WangZ, SunH, GongH, ZhangZ. CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma. Biomarkers14, 480–485 (2009).
  • Jin B , HuangAM, ZhongRB, HanBH. The value of tumor markers in evaluating chemotherapy response and prognosis in Chinese patients with advanced non-small cell lung cancer. Chemotherapy56, 417–423 (2010).
  • Zhu WQ , YuJM, SunXD, XieP, KongL. Serum CYFRA21-1 as a prognostic marker for patients with undifferentiated nasopharyngeal carcinoma. Biomarkers15, 602–607 (2010).
  • Alkotyfan K , WiegandS, MullerHH, WindfuhrJP, WernerJA, SesterhennAM. Cyfra21-1 as a tumor marker for follow-up of patients with squamous cell carcinoma of the oropharynx. Anticancer Res.30, 2291–2296 (2010).
  • Lindberg K , RheinwaldJG. Suprabasal 40 kd keratin (K19) expression as an immunohistologic marker of premalignancy in oral epithelium. Amer. J. Pathol.134, 89–98 (1989).
  • Balch CM , GershenwaldJE, SoongSJet al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 6199–6206 (2009).
  • Al-Shagahin H , AlkotyfanK, MullerHH, SesterhennAM, WernerJA. Cyfra21-1 as a serum tumor marker for follow-up of patients with laryngeal and hypopharyngeal squamous cell carcinoma. Anticancer Res.29, 3421–3426 (2009).
  • Sheard MA , VojtesekB, SimickovaM, ValikD. Release of cytokeratin 18 and 19 fragments (TPS and CYFRA21-1) into the extracellular space during apoptosis. J. Cell. Biochem.85, 670–677 (2002).
  • Trap é J , BuxoJ, Pérez de OlaguerJ, VidalC. Tumor markers as prognostic factor in treated non-small cell lung cancer. Anticancer Res. 23, 4277–4281 (2003).
  • Muley T , DienemannH, EbertW. CYFRA21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients. Anticancer Res.24, 1953–2004 (1956).
  • Kosacka M , JankowskaR. Comparison of cytokeratin 19 expression in tumor tissue and serum CYFRA21-1 levels in non small cell lung cancer. Pol. Arch. Med. Wewn119, 33–38 (2009).
  • Huang MS , JongSB, LinMSet al. Cytokeratin fragment 19 (CYFRA21-1) as a tumor marker in non-small cell lung cancer. Kaohsiung J. Med. Sci. 12, 62–68 (1996).
  • Wu F , NishiokaM, FujitaJet al. Expression of cytokeratin 19 in human hepatocelluar carcinoma cell lines. Int. J. Oncol. 20, 31–37 (2002).
  • Nakamura H , AbeS,Shibata Y et al. Elevated levels of cytokeratin 19 in the bronchoalveolar lavage fluid of patients with chronic airway inflammatory diseases: a specific marker for bronchial epithelial injury. Am. J. Respir. Crit. Care Med.155, 1217–1221 (1997).
  • Nakayama M , SatohH, IshikawaHet al. Cytokeratin 19 fragment in patients with nonmalignant respiratory diseases. Chest 123, 2001–2003 (2006).
  • Dobashi N , FujitaJ, OhtsukiYet al. Elevated serum and BAL cytokeratin 19 fragment in pulmonary fibrosis and acute interstitial pneumonia. Eur. Respir. J. 14, 574–578 (1999).
  • Chyczewski L , NiklinskiJ, ChyczewskaE, LaudanskiJ, FurmanM. Immunohistochemical analysis of tissue localization of cytokeratin 19 in lung cancer. Rocz Akad. Med. Bialymst.42(Suppl. 1), 162–172 (1997).
  • Lai RS , HsuHK, LuJY, GerLP, LaiNS. CYFRA21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer. Chest109, 995–1000 (1996).
  • Takahashi H , KurishimaK, IshikawaH, KagohashiK, KawaguchiM, SatohH. Optimal cutoff points of CYFRA21-1 for survival prediction in non-small cell lung cancer patients based on running statistical analysis. Anticancer Res.30, 3833–3837 (2010).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.